Single-Pill Hypertension Therapy Remains Underutilized
A recent study found that single-pill combination therapy for hypertension is underutilized among newly diagnosed patients in the US. Despite guidelines recommending this treatment, only 5.88% of patients initiated it between 2015 and 2025. The study highlights a gap between clinical practice and established recommendations.
- ▪Fewer than 1 in 10 US adults with a new diagnosis of hypertension were started on single-pill combination therapy.
- ▪Over the study period, the initiation of single-pill combination therapy declined by 6.56% per year.
- ▪In patients with stage 2 hypertension, the initiation of single-pill combination therapy was even lower at 5.46%.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Despite guideline recommendations in 2017 and 2025, fewer than 1 in 10 US adults with a new diagnosis of hypertension were started on single-pill combination therapy. Prescriptions did not increase over the 10-year study period, as per a brief report published in the Journal of the American College of Cardiology (JACC).METHODOLOGY:Researchers conducted a retrospective observational study using the Epic Cosmos electronic health record database to assess how often adults newly diagnosed with hypertension were started on single-pill combination therapy.They included over 7.2 million US adult patients newly diagnosed with hypertension between 2015 and 2025.Patients had at least 1 year of prior records and initiated antihypertensive medications such as angiotensin-converting enzyme…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
